- Home
- CBIO vs XRPN Comparison
CBIO vs XRPN Comparison
Compare CBIO & XRPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CBIO | XRPN |
|---|---|---|
| Founded | 2003 | 2024 |
| Country | | |
| Employees | N/A | N/A |
| Industry | | Blank Checks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.7M | 323.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CBIO | XRPN |
|---|---|---|
| Price | $11.84 | $10.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $27.17 | N/A |
| AVG Volume (30 Days) | ★ 207.9K | 110.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $72.74 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.72 | $10.10 |
| 52 Week High | $17.39 | $10.35 |
Technical Indicators
Market Signals| Indicator | CBIO | XRPN |
|---|---|---|
| Relative Strength Index (RSI) | 60.97 | 69.49 |
| Support Level | $8.76 | $10.23 |
| Resistance Level | $9.69 | $10.26 |
| Average True Range (ATR) | 0.87 | 0.02 |
| MACD | 0.18 | 0.00 |
| Stochastic Oscillator | 94.83 | 100.00 |
Price Performance
Historical ComparisonAbout CBIO Crescent Biopharma Inc.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About XRPN Armada Acquisition Corp. II Class A Ordinary Shares
Armada Acquisition Corp II is a blank check company.